Enlivex Therapeutics Webinar on Osteoarthritis Innovations
Nes-Ziona, Israel – Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a dynamic company focusing on macrophage reprogramming immunotherapy, is set to participate in an engaging investor webinar. This event titled "Advancing Inflammatory Disease Treatment: Insights & Breakthroughs from Enlivex's Knee Osteoarthritis Program," promises to highlight the company's latest advancements and is hosted by D. Boral Capital.
Insights from Leading Experts
Taking place at 10:00 AM Eastern Time, the webinar will feature prominent figures in musculoskeletal disease research, including Enlivex’s Vice Chairman. Their collaboration aims to present the exciting developments in knee osteoarthritis (KOA) treatments, particularly focusing on the significant Phase IIa topline data from Enlivex's groundbreaking Allocetra™ program. This program targets individuals suffering from moderate-to-severe KOA, a demographic that has long faced treatment challenges.
Positive Outcomes from Clinical Data
The recent data from the Phase IIa trial showcased a remarkable reduction in pain and substantial improvements in functionality for patients with idiopathic, age-related knee osteoarthritis, which represents a large, underserved patient base. This progress is not only encouraging for Enlivex but also pivotal for healthcare professionals treating this condition.
Who Will Be Speaking?
The webinar will feature an exclusive panel of esteemed experts:
Professor Ali Mobasheri, Ph.D
A revered Professor of Musculoskeletal Biology at the University of Oulu in Finland. With a wealth of experience, including previous leadership at the Osteoarthritis Research Society International (OARSI), he is a trusted advisor to the WHO on musculoskeletal health and has an impressive portfolio of over 400 scientific publications in cartilage biology and osteoarthritis biomarkers.
Professor Philip Conaghan, MBBS, PhD, FRACP, FRCP
A Consultant Rheumatologist and Director of the NIHR Leeds Biomedical Research Centre. Renowned for his contributions to osteoarthritis and musculoskeletal imaging, he has authored over 700 publications and has led multiple global guideline and trial initiatives.
Dr. Roger Pomerantz, M.D.
As the Vice Chairman of Enlivex Therapeutics, his extensive experience spans decades as a physician-scientist and biotech executive. His expertise has been instrumental in guiding several therapies from their initial stages through to successful commercialization.
Jason Kolbert, M.Sc.
Bringing over 20 years of experience as the Managing Director of Healthcare Research at D. Boral Capital, his unique perspective combines insights from both pharmaceutical development and equity research in healthcare.
CEO's Vision for the Future
Oren Hershkovitz, Ph.D., CEO of Enlivex, expressed enthusiasm about the webinar, stating, "We are excited to bring together some of the world’s foremost experts to discuss the significant potential of Allocetra™ to potentially change the treatment paradigm for millions suffering from knee osteoarthritis. The lack of approved disease-modifying therapies heightens the importance of our positive Phase IIa data as we push towards late-stage clinical development."
About Enlivex Therapeutics
Enlivex is innovating in the field of macrophage reprogramming immunotherapy with its pioneering product, Allocetra™. This therapy is designed to reset macrophages to their homeostatic state, which plays a crucial role in balancing the immune system and addressing severe health issues. To discover more about their initiatives, visit Enlivex's official website.
Frequently Asked Questions
What is the main focus of the webinar?
The webinar centers around advancements in the treatment of knee osteoarthritis, showcasing insights and breakthroughs from Enlivex's program.
Who are the speakers at the webinar?
Experts include Professor Ali Mobasheri, Professor Philip Conaghan, Dr. Roger Pomerantz, and Jason Kolbert, each significant figures in musculoskeletal disease research.
What is Allocetra™?
Allocetra™ is a novel macrophage reprogramming cell therapy developed by Enlivex, aiming to restore immune system balance in patients.
How can participants register for the webinar?
Interested individuals can register online to secure their spot for the event.
What is the significance of the Phase IIa data?
The Phase IIa data has shown promising results in reducing pain and improving functionality in patients with knee osteoarthritis, indicating great potential for future treatments.
